BRIAN J. TERRY, Ph.D.

Middletown, CT

(860)347-7084

SUMMARY

Experienced biochemist with extensive drug discovery and preclinical evaluation of antivirals against HIV, Hepatitis B virus and herpesviruses while working at Bristol-Myers Squibb. Proven team building skills and successful completion of group and departmental goals.

  • Detailed understanding of drug discovery
/
  • Cell Culture
/
  • BSL-3 Manager

  • Hit to lead optimization
/
  • Enzymology
/
  • Mentoring

  • Hands-on HIV experience
/
  • Virology
/
  • Medical Writing

  • Assay Development
/
  • Analytical abilities
/
  • Member corporate biosafety committee

  • Biochemistry
/
  • Effective team work
/
  • Early clinical development team member

PROFESSIONAL EXPERIENCE

Bristol-Myers Squibb, Wallingford, CT1997-2012

Senior Research Investigator II

Investigated mechanism of action of hepatitis B virus and HIV inhibitors.

  • Personally wrote Virology Sections of INDs and NDAs for two billion dollar drugs (Reyataz and Baraclude); required coordinating biochemistry, cell culture and animal studies
  • Extensive experience in drug discovery from early discovery to clinical stage
  • Assay optimization to support drug discovery
  • Mechanism of action studies involving resistance, enzyme kinetics and phosphorylation studies
  • Hit to lead optimization
  • Hands-on experience with HIV laboratory strains and clinical isolates
  • BSL-3 Lab Manager for 7 years
  • Resistance selection for HIV inhibitors and phenotyping

BRIAN J. TERRYPAGE TWO

  • Established feasibility of using adnexins as inhibitors of HIV
  • Analyzed HIV drug combination studies for strategic and regulatory purposes
  • Isolation and inhibitor studies of recombinant HIV integrases
  • Ability to collaborate and perform in highly effective teams
  • Member of Early Development Team for clinical development of entecavir
  • Charter member of Infectious Disease Lead Profiling Group charged with quickly and rigorously analyzing hits from in-licensed programs

Bristol-Myers Squibb, Wallingford, CT and Lawrenceville, NJ1990-1997

Senior Research Investigator I

  • Discovery and early characterization of entecavir (Baraclude) for HBV
  • Mechanism of action of herpes, HIV and hepatitis B antivirals
  • Isolation and characterization of recombinant HIV and HCV proteases
  • Enzyme kinetics by radiochemical, spectroscopic and fluorimetric techniques
  • Wrote five INDapplications and one NDA application
  • Member of Early Development Team for two herpesvirus compounds

Squibb/Bristol-Myers Squibb, Lawrenceville, NJ1987-1990

Research Investigator

Mechanism of action of herpes antivirals (phosphorylation, kinetics). Isolation and characterization of viral and recombinant enzymes. Extensive protein isolation and HPLC experience.

EDUCATION

Post-Doctoral Fellow – Duke University Medical Center, Durham, North Carolina

Ph.D. in Chemistry (Biochemistry) – University of California, Santa Barbara Doctoral Thesis: Nucleotide Interactions in Brain Microtubule Assembly

B.S. in Chemistry – University of Michigan, Ann Arbor

AWARDS

Bristol-Myers Squibb Presidential Award for Lobucavir Filing Team in China for Hepatitis B (1999)

Bristol-Myers Squibb Presidential Award for Zerit FDA approval (1995)

PUBLICATIONS

Thirty (31) publications, 21 at Bristol-Myers Squibb (Appendix available)

BRIAN J. TERRYAPPENDIX

PUBLICATIONS

  1. Li, Z., B. Terry, W. Olds, T. Protack, C. Deminie, B. Minassian, B. Nowicka-Sans, Y. Sun, I. Dicker, C. Hwang, M. Lataillade, G.J. Hanna, and M. Krystal. 2013. In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations. Antimicrob. Agents Chemotherap. 57:5500-5508.
  1. Dicker, I.B., M.A. Walker, Z. Lin, B. Terry, L. Pajor, M. Zheng, B.N. Naidu, J. Banville, N. Meanwell, and M. Krystal. 2011. Simple and Accurate In Vitro Method for Predicting Serum Protein Binding of HIV Integrase Strand Transfer Inhibitors. HIV-1 Integrase: Mechanism and Inhibitor Design (Neamati, N., ed.) 275-284, Wiley & Sons, New Jersey.
  1. Lin, P.-F., B. Nowicka-Sans, B. Terry, S. Zhang, C. Wang, L. Fan, I. Dicker, V. Gali, H. Higley, N. Parkin, D. Tenney, M. Krystal, and R. Colonno. 2008. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob. Agents Chemotherap. 52:1759-1767.
  1. Dicker, I.B., B. Terry, Z. Lin, Z. Li, S. Bollini, H.K. Samanta, V. Gali, M.A. Walker, and M.R. Krystal. 2008. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J. Biol. Chem. 283:23599-23609.
  1. Walker, M.A., T. Johnson, Z. Ma, Y. Zhang, J. Banville, R. Remillard, S. Plamondon, A. Pendri, H. Wong, D. Smith, A. Torri, H. Samanta, Z. Lin, C. Deminie, B. Terry, M. Krystal, and N. Meanwell. 2006. Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype. Bioorg. Med. Chem. Lett. 16:5818-5821.
  1. Walker, M.A., T. Johnson, Z. Ma, J. Banville, R. Remillard, O. Kim, Y. Zhang, A. Staab, H. Wong, A. Torri, H. Samanta, Z. Lin, C. Deminie, B. Terry, M. Krystal, and N. Meanwell. 2006. Triketoacid inhibitors of HIV-1 integrase. A new chemotype useful for probing the integrase pharmacophore. Bioorg. Med. Chem. Lett. 16:2920-2924.
  1. Robinson, B.S., K.A. Riccardi, Y.-F. Gong, Q. Guo, D.A. Stock, W.S. Blair, B.J. Terry, C.A. Deminie, F. Djang, R.J. Colonno,, and P.-F. Lin. 2000. BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents. Antimicrob. Agents Chemotherap. 44:2093-2099.
  1. Rose, R.E., Y.-F. Gong, J.A. Greytok, C.M. Bechtold, B.J. Terry, B.S. Robinson, M. Alam, R.J. Colonno, and P.-F. Lin. 1996. Human immunodeficiency virus type 1 background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
  1. Chung, T.D.Y., C. Cianci, M. Hagen, B. Terry, J.T. Matthews, M. Krystal, and R.J. Colonno. 1994. Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc. Natl. Acad. Sci. USA 91:2372-2376.
  1. Kim, C.U., P.F. Misco, B.Y. Luh, B. Terry, G. Bisacchi, and M.M. Mansuri. 1993. (2R, 4S, 5S)-1-(Tetahydro-4-hydroxy-5-methoxy-2-furanyl)thymine: A Potent and Selective Inhibitor of Herpes Simplex Thymidine Kinase. Bioorg. Med. Chem. Lett. 3:1571-1576.
  1. Matthews, J.T., B.J. Terry, and A.K. Field. 1993. The Structure and Function of the HSV DNA Replication Proteins: Defining Novel Antiviral Targets. Antiviral Res. 20:89-114.
  1. Terry, B.J., W.-C. Liu, C.W. Cianci, E. Proszynski, P. Fernandes, K. Bush, and E. Meyers. 1992. Inhibition of Herpes Simplex Virus Type 1 DNA Polymerase by the Natural Product Oosporein. J. Antibiotics 45:286-288.
  1. Terry, B.J., C.W. Cianci, and M.E. Hagen. 1991. Inhibition of HSV-1 DNA Polymerase by (1R-(1α,2β,3α)-9-[2,3-Bis(hydroxymethyl)cyclobutyl]guanine. Mol. Pharmacol. 40:591-596.
  1. Yamanaka, G., A.V. Tuomari, M. Hagen, B. McGeever-Rubin, B. Terry, M. Haffey, G.S. Bisacchi, and A.K. Field. 1991. Selective Activity and Cellular Pharmacology of (1R-(1α,2β,3α)-9-[2,3-Bis(hydroxymethyl)cyclobutyl] guanine. Mol. Pharmacol. 40:446-453.
  1. Yamanaka, G., A.V. Tuomari, M. Christodoulides, B.J. Terry, and A.K. Field. 1991. (R)-BHCA, SQ-34990: A Dihydroxymethylcyclobutyl Deoxyadenosine Analog Active Against Ganciclovir Resistant HCMV. Proc. 3rd Intl. CMV Workshop, Bologna, Italy, Elsevier, 341-344.
  1. Bisacchi, G.S., A. Braitman, C.W. Cianci, J.M. Clark, A.K. Field, M.E. Hagen, D.R. Hockstein, M.F. Malley, T. Mitt, W.A. Slusarchyk, J.E. Sundeen, B.J. Terry, A.V. Tuomari, E.R. Weaver, M.G. Young, and R. Zahler. 1991. Synthesis and Antiviral Activity of Enantiomeric Forms of Cyclobutyl Nucleoside Analogs. J. Med. Chem. 34:1415-1421.
  1. Terry, B.J., K.E. Mazina, A.V. Tuomari, M.E. Hagen, M.L. Haffey, G.A. Jacobs, R. Zahler, and A.K. Field. 1990. Anti-Herpetic Activity of (±)-(1α,2β,3α)-9-[2-hydroxy-3-(hydroxymethyl)cyclobutyl]guanine, A New Cyclobutane Guanosine Analog. Antiviral Chem. Chemotherap. 1:263-268.
  1. Matthews, J.T., J.T. Stevens, B.J. Terry, C.W. Cianci, and M.L. Haffey. 1990. Neutralization of Purified Herpes Simplex DNA Polymerase by Two Antipeptide Sera. Virus Genes 3:343-354.
  1. Field, A.K., A.V. Tuomari, B. McGeever-Rubin, B.J. Terry, K.E. Mazina, M.L. Haffey, M.E. Hagen, J.M. Clark, A. Braitman, W.A. Slusarchyk, M.G. Young, and R. Zahler. 1990. (±)-(1α,2β,3α)-9-[2,3-Bis(hydroxymethyl)cyclobutyl] guanine [(±)-BHCG or SQ 33054]: A Potent and Selective Inhibitor of Herpesviruses. Antiviral Res. 13:41-52.
  1. Haffey, M.L., J.T. Stevens, B.J. Terry, D.I. Dorsky, C.S. Crumpacker, S.M. Wietstock, W.T. Ruyechan, and A.K. Field. 1988. Expression of Herpes Simplex Virus Type -1 DNA Polymerase in Saccharomyces cerevesiae and the Detection of Viral Specific Enzyme Activity in Cell Free Lysates. J. Virol. 62:4493-4498.
  1. Terry, B.J., K.E. Mazina, A.V. Tuomari, M.L. Haffey, M. Hagen, A. Feldman, W.A. Slusarchyk, M.G. Young, R. Zahler, and A.K. Field. 1988. Broad Spectrum Antiviral Activity of the Acyclic Guanosine Phosphonate (R,S)-HPMPG. Antiviral Res. 10:235-252.
  1. Terry, B.J., W.E. Jack, and P. Modrich. 1987. Mechanism of Specific Site Location and DNA cleavage by EcoRI Endonuclease. Gene Amplification and Analysis: Volume 5 (Chirikjian, J.G., ed.), 103-118.
  1. Terry, B.J., W.E. Jack, and P. Modrich. 1985. Facilitated Diffusion Catalysis by EcoRI Endonuclease. J. Biol. Chem. 260:13130-13137.
  1. Terry, B.J., W.E. Jack, R.A. Rubin, and P. Modrich. 1983. Thermodynamic Parameters Governing Interaction of EcoRI Endonuclease with Specific and Nonspecific DNA Sequences. J. Biol. Chem. 258:9820-9825.
  1. Jack, W.E., Terry, B.J., and P. Modrich. 1982. Involvement of Outside DNA Sequences in the Major Path by Which EcoRI Endonuclease Locates and Leaves Its Recognition Sequence. Proc. Natl. Acad. Sci. USA 79:4010-4014.
  1. Kristofferson, D., S.H. Lee, B.J. Terry, A.C. Saucier, T.L. Karr, and D.L. Purich. 1982. Evaluation of Potential Roles for GDP in Microtubule Assembly and Disassembly. Biological Functions of Microtubules and Related Structures (Sakai, H., H. Mohri, and G.G. Borisy, eds.) 49-60, Academic Press, New York
  1. Purich, D.L., B.J. Terry, R.K. MacNeal, and T.L. Karr. 1982. Characterization of Tubulin and Microtubule Associated Protein Interactions with Guanine Nucleotides and Their Nonhydrolyzable Analogues. Methods in Enzymology 85:416-433.
  1. Terry, B.J., and D.L. Purich. 1982. Nucleotide-Dependent Enzymes Associated with Microtubule Systems. Advances in Enzymology 53:113-161.
  1. Purich, D.L., B.J. Terry, H.D. White, B.A. Coughlin, T.L. Karr, and D. Kristofferson. 1981. Microtubule Associated Protein Phosphorylation and Calcium Ion Regulation of Bovine Brain Microtubule Self-Assembly. Protein Phosphorylation (Rosen, O.M., and E.G. Krebs, eds.), Book B, 1143-1155, ColdSpringHarbor Laboratory, New York.
  1. Terry, B.J., and D.L. Purich. 1980. Assembly and Disassembly Properties of Microtubules Formed in the Presence of GTP, 5’-Guanylyl Imidodiphosphate, and 5’-Guanylyl Methylenediphosphate. J. Biol. Chem. 255:10532-10536.
  1. Terry, B.J., and D.L. Purich. Nucleotide Release from Tubulin and Nucleoside-5’-Diphosphate Kinase Action in Microtubule Assembly. J. Biol. Chem. 254:9469-9476.